Comparison of the influence of four classes of HIV antiretrovirals on adipogenic differentiation: The minimal effect of raltegravir and atazanavir

Journal of Infection and Chemotherapy

Volumn 17, Issue 2, 2011, Pages 183-188

  Minami, Rumi ^a   Yamamoto, Masahiro ^a   Takahama, Soichiro ^a   Ando, Hitoshi ^a   Miyamura, Tomoya ^a   Suematsu, Eiichi ^a  

^a NATIONAL HOSPITAL ORGANIZATION   (Japan)

Author keywords

Adipocyte; Antiretrovirals; HIV 1; Lipodystrophy

Indexed keywords

ABACAVIR; AMPRENAVIR; ATAZANAVIR; CATALASE; CCAAT ENHANCER BINDING PROTEIN ALPHA; EFAVIRENZ; LAMIVUDINE; LOPINAVIR; NELFINAVIR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RALTEGRAVIR; RITONAVIR; STAVUDINE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; SUPEROXIDE DISMUTASE; ZIDOVUDINE;

ADIPOCYTE; ADIPOGENESIS; ARTICLE; CAAT BOX ENHANCER BINDING PROTEIN ALPHA GENE; CELL DIFFERENTIATION; CELL STRAIN 3T3; CONTROLLED STUDY; GENE; GENE EXPRESSION; IN VITRO STUDY; LIPID METABOLISM; LIPID STORAGE; OXIDATIVE STRESS; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA GENE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C GENE;

EID: 79955902960     PISSN: 1341321X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10156-010-0101-5     Document Type: Article

References (20)

1. Stanley TL, Joy T, Hadigan CM, Liebau JG, Makimura H, Chen CY, et al. Effects of switching from lopinavir/ritonavir to atazanavir/ritonavir on muscle glucose uptake and visceral fat in HIV-infected patients. AIDS. 2009;23:1349-57.
2. Haerter G, Manfras BJ, Mueller M, Kern P, Trein A. Regression of lipodystrophy in HIV-infected patients under therapy with the new protease inhibitor atazanavir. AIDS. 2004;18:952-5. (Pubitemid 38553719)
3. Stankov MV, Schmidt RE, Behrens GM. German Competence Network HIV/AIDS. Zidovudine impairs adipogenic differentiation through inhibition of clonal expansion. Antimicrob Agents Chemother. 2008;52:2882-9.
4. Kim RJ, Wilson CG, Wabitsch M, Lazar MA, Steppan CM. HIV protease inhibitor-specific alterations in human adipocyte differentiation and metabolism. Obesity (Silver Spring). 2006; 14:994-1002. (Pubitemid 46219700)
5. Cianflone K, Zakarian R, Stanculescu C, Germinario R. Protease inhibitor effects on triglyceride synthesis and adipokine secretion in human omental and subcutaneous adipose tissue. Antivir Ther. 2006;11:681-91. (Pubitemid 44497163)
6. Flint OP, Noor MA, Hruz PW, Hylemon PB, Yarasheski K, Kotler DP, et al. The role of protease inhibitors in the pathogenesis of HIV-associated lipodystrophy: cellular mechanisms and clinical implications. Toxicol Pathol. 2009;37:65-77.
7. Lagathu C, Eustace B, Prot M, Frantz D, Gu Y, Bastard JP, et al. Some HIV antiretrovirals increase oxidative stress and alter chemokine, cytokine or adiponectin production in human adipocytes and macrophages. Antivir Ther. 2007;12:489-500. (Pubitemid 47041147)
8. Rosen ED, Walkey CJ, Puigserver P, Spiegelman BM. Transcriptional regulation of adipogenesis. Genes Dev. 2000; 14:1293-307. (Pubitemid 30397073)
9. Bastard JP, Caron M, Vidal H, Jan V, Auclair M, Vigouroux C, et al. Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet. 2002;359:1026-31. (Pubitemid 34286541)
10. Hirano Y, Yoshida M, Shimizu M, Sato R. Direct demonstration of rapid degradation of nuclear sterol regulatory element-binding proteins by the ubiquitin-proteasome pathway. J Biol Chem. 2001;276:36431-7.
11. Dowell P, Flexner C, Kwiterovich PO, Lane MD. Suppression of preadipocyte differentiation and promotion of adipocyte death by HIV protease inhibitors. J Biol Chem. 2000;275:41325-32. (Pubitemid 32054966)
12. Parker RA, Flint OP, Mulvey R, Elosua C, Wang F, Fenderson W, et al. Endoplasmic reticulum stress links dyslipidemia to inhibition of proteasome activity and glucose transport by HIV protease inhibitors. Mol Pharmacol. 2005;67:1909-19. (Pubitemid 41007773)
13. Caron M, Vigouroux C, Bastard JP, Capeau J. Antiretroviral-related adipocyte dysfunction and lipodystrophy in HIV-infected patients: alteration of the PPARgamma-dependent pathways. PPAR Res. 2009;2009:507141.
14. Stankov MV, Lücke T, Das AM, Schmidt RE, Behrens GM. Relationship of mitochondrial DNA depletion and respiratory chain activity in preadipocytes treated with nucleoside reverse transcriptase inhibitors; German Competence Network HIV/ AIDS. Antivir Ther. 2007;12:205-16.
15. Eron JJ, Young B, Cooper DA, Youle M, Dejesus E, Andrade-Villanueva J, et al. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet. 2010;375:396-407.
16. Green H, Kehinde O. An established preadipose cell line and its differentiation in culture. Cell. 1975;5:19-27.
17. Kamigaki M, Sakaue S, Tsujino I, Ohira H, Ikeda D, Itoh N, et al. Oxidative stress provokes atherogenic changes in adipokine gene expression in 3T3-L1 adipocytes. Biochem Biophys Res Commun. 2006;339:624-32. (Pubitemid 41739713)
18. Ben-Romano R, Rudich A, Etzion S, Potashnik R, Kagan E, Greenbaum U, et al. Nelfinavir induces adipocyte insulin resistance through the induction of oxidative stress: differential protective effect of antioxidant agents. Antivir Ther. 2006;11:1051-60. (Pubitemid 44955181)
19. Masiá M, Padilla S, Bernal E, Almenar MV, Molina J, Hernández I, et al. Influence of antiretroviral therapy on oxidative stress and cardiovascular risk: a prospective cross-sectional study in HIVinfected patients. Clin Ther. 2007;29:1448-55. (Pubitemid 47354208)
20. El Hadri K, Glorian M, Monsempes C, Dieudonné MN, Pecquery R, Giudicelli Y, et al. In vitro suppression of the lipogenic pathway by the nonnucleoside reverse transcriptase inhibitor efavirenz in 3T3 and human preadipocytes or adipocytes. J Biol Chem. 2004;279:15130-41.